Jan Westerman
Pulmonary Disease · Jasper, ALNPI 1285674150
Payments from drug & device makers
Across 211 payments — averaging $3951.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$274K
- Boehringer Ingelheim$116K
- AstraZeneca$104K
- Sanofi US Services Inc.$83K
- Hoffmann-la Roche Limited$73K
- Novartis$68K
- plus $117K from 21 others
Across 6 payments — averaging $2863.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- First Wave Biopharma, Inc.$10K
- Eli Lilly$8K
What the payments were for
- Travel & lodging$1,11943%
- Food & beverage$1,50157%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 33 | $273,586 |
| Boehringer Ingelheim | 16 | $115,523 |
| AstraZeneca | 28 | $103,870 |
| Sanofi US Services Inc. | 22 | $83,009 |
| Hoffmann-la Roche Limited | 10 | $72,836 |
| Novartis | 2 | $67,779 |
| GSK | 34 | $38,595 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 3 | $33,196 |
| United Therapeutics Corporation | 5 | $20,171 |
| Chiesi USA, Inc. | 3 | $13,700 |
| Mylan Specialty L.p. | 3 | $9,500 |
| Olympus Corporation Of The Americas | 7 | $1,148 |
| Philips North America LLC | 11 | $212 |
| Axsome Therapeutics, Inc. | 6 | $108 |
| Harmony Biosciences LLC | 5 | $105 |
| Grifols USA, LLC | 5 | $98 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Circassia Inc. | 2 | $38 |
| Amgen(2 entities) | 2 | $38 |
| Insmed, Inc. | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Mallinckrodt Enterprises LLC | 2 | $32 |
| Genentech USA, Inc. | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $20 |
| Vapotherm Inc | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Spiration Valve System$1,029
How this compares
$833,775 in reported general payments places this provider in the 95th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 26 | $329,972 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $74,810 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 46 | $21,826 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $17,972 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $16,588 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $16,331 |
| Spiriva RespimatTiotropium Bromide | 16 | $8,223 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 117 | $3,954 |
| Arnuity ElliptaFluticasone Furoate | 13 | $2,720 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 101 | $2,478 |
| Roflumilast | 22 | $2,240 |
| Azithromycin | 98 | $1,710 |
| Dextroamphetamine Sulfate | 19 | $1,489 |
| Modafinil | 14 | $927 |
| Armodafinil | 13 | $863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C | $98 | $329,97226 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $38,595 | $112,089198 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $115,523 | $30,04962 claims |
| AstraZenecaBreztri Aerosphere | $103,870 | $16,33119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Jasper
- Robert GarverAndalusia$4.6M
- Allan SeibertMobile$2.4M
- Tejaswini KulkarniBirmingham$1.7M
- Bryan GarciaBirmingham$606K
- A RidgewaySheffield$434K
- Darryle BullardCullman$380K
- Marvin SextonDothan$346K
- Veena AntonyBirmingham$327K
- William SaliskiMontgomery$257K
- Steven RoweBirmingham$252K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.